ALT-711
Phase 2Small molecule
ALT-711 is one of 75 small molecule programs targeting Diastolic Heart Failure. It is currently in Phase 2.
3
Indications
8
Total Trials
0
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1ALT-711
SSynvista Therapeutics, Inc
Phase 2
Monoferric
PPharmacosmos A/S
Preclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Coumadin
AAbbott
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension2 trials
Heart Failure2 trials
Diastolic Heart Failure1 trial
Exercise Training1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALT-711. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSynvista Therapeutics, Inc